Related references
Note: Only part of the references are listed.Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma
Rebeca Manso et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Targeting histone deacetylases in T-cell lymphoma
Alison J. Moskowitz et al.
LEUKEMIA & LYMPHOMA (2017)
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
Sung Hoon Sim et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma
M. Gupta et al.
ANNALS OF ONCOLOGY (2016)
Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
A. M. Roncero et al.
LEUKEMIA (2016)
Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL
Wenming Wang et al.
ONCOLOGY REPORTS (2016)
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma
Daniel Beck et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
Melanie R. Hassler et al.
CELL REPORTS (2016)
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
Lu Jiang et al.
NATURE GENETICS (2015)
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
Jehan Dupuis et al.
LANCET HAEMATOLOGY (2015)
Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma
Thomas E. Witzig et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
Georg Hopfinger et al.
ANNALS OF HEMATOLOGY (2014)
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Bertrand Coiffier et al.
CANCER TREATMENT REVIEWS (2014)
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy
T. E. Witzig et al.
LEUKEMIA (2014)
Pathology of Peripheral T-Cell Lymphomas: Where Do We Stand?
Philippe Gaulard et al.
SEMINARS IN HEMATOLOGY (2014)
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas
Linda Sooman et al.
TUMOR BIOLOGY (2014)
The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
R. Briski et al.
BLOOD CANCER JOURNAL (2014)
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
Mamta Gupta et al.
BLOOD (2012)
Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
Mamta Gupta et al.
BLOOD (2012)
DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies
Jacques Fahy et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Inborn Errors of Human JAKs and STATs
Jean-Laurent Casanova et al.
IMMUNITY (2012)
Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Ghee Chong Koo et al.
CANCER DISCOVERY (2012)
JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
A. Tefferi et al.
BLOOD REVIEWS (2011)
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia
Maria Kleppe et al.
NATURE GENETICS (2010)
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
Mamta Gupta et al.
BLOOD (2009)
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Mamta Gupta et al.
BLOOD (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter
Li-Peng Wu et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
David Herman et al.
NATURE CHEMICAL BIOLOGY (2006)
Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma
Y. Han et al.
LEUKEMIA (2006)
TYK2 and JAR2 are substrates of protein-tyrosine phosphatase 1B.
MP Myers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b
N Aoki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)